RH-PRIVÉ
6.8.2024 14:21:33 CEST | Business Wire | Press release
RH Privé, the leading developer of eco luxury homes on the Costa del Sol, has called on the acclaimed design studio Pininfarina for an exclusive conceptual interior design project. With designs of some of the most iconic sports cars in the automotive history and outstanding architectural projects such as the majestic ICONIC tower in Dubai in his charge, this collaboration aims to further enhance the exclusivity and luxury of the developer's most exclusive development: Carat Sky Villas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240806233462/en/
RH Privé unveils two of the world’s most desirable luxury penthouses in Costa del Sol. (Photo: RH Privé)
The penthouses are currently under construction, with delivery expected by the end of the year. In their initial conceptualization, the orientation of each dwelling has played a fundamental role, one ‘floating on the sea’ and the other ‘immersed in the mountains’. Each penthouse has been designed based on a well-differentiated conceptual theme: the first incorporates nautical motifs and the second is inspired by different wood textures, with the intention of integrating nature into the home.
“We are proud to partner with Pininfarina. Our union has allowed us not only to align our values, but also to share experiences, ideas and cultures to result in the project of two exclusive penthouses, unique in Spain”, says Guillermo Rodríguez, CEO of RH Privé.
Carat Sky Villas: a unique experience with sustainability as its core
Both penthouses belong to Carat Sky Villas and are strategically located in the majestic enclave of Reserva del Higuerón, where residents can enjoy the best views of the Mediterranean Sea from the Costa del Sol, as well as large open garden spaces alligned with nature.
Talking about sustainability, Carat Sky Villas stands out for its water saving system based on the reuse of rainwater, decalcification and hydro-efficient taps. It also stands out for its maximum energy efficiency model based on an aerothermal system, individual ventilation and the use of large windows to make the most of natural light. Besides, apart from recycling 70% of the construction materials, RH Privé guarantees respect for the biodiversity of the environment by planting native species in the landscaping design and reforesting the area surrounding the development.
In addition, the homes will benefit from the installation of the latest technology on the market, with a domotic system that allows the control of lighting, access and air conditioning, among many other functions, being able to control everything remotely at any time.
Interior design philosophy and superb amenities
In the heart of these penthouses, borders do not exist, overcoming limits and creating spaces for unique moments. The Sea plays a fundamental role in the design of the spaces. The floors are oriented towards the sea, creating spaces flooded with natural light and offering unforgettable sunsets. Thanks to the large windows, the line between indoors and outdoors is blurred, accentuating the sensation of floating above the sea provided by the infinity pool.
Carat’s welcomes you to the community in which only a select few can live. An excellent wellness area consisting of a salt cave, massage room, hammam, sauna and an indoor heated pool that completes the spa area. For the sportiest Carat offers a luxury gym equipped with Technogym machines, featuring its exclusive Christian Dior equipment. Owners can also enjoy the cinema room, a coworking area with sea views and an outdoor space consisting of an infinity pool, pool bar and solarium. But that's not all, as the promotion will feature a 5-star concierge service, allowing owners to forget about tedious chores.
Download the complete image asset of the interiors here.
About RH Privé
RH Privé is the leading real estate promoter in sustainable luxury development in Spain. After more than 30 years of success in Reserva del Higuerón, in the heart of Costa del Sol, the figures speak for themselves: more than 500 homes delivered, more than 200 under construction and more than 160 recently launched on the market. Always committed to eco-luxury development, each construction enjoys the unique stamp of RH Privé under ESG criteria. With a future full of new projects and ambitions, sustainability plays and will play a key role at the heart of the company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806233462/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom